MODERNA SUBMITS REGULATORY APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR ITS UPDATED COVID-19 VACCINE
The filing follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Jul 23
The filing follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines
04 Jul 23
Launches authorized generic for Xyrem (sodium oxybate) in the US, representing another new complex generic product launch
03 Jul 23
Hyrimoz HCF is approved in the US to treat indications including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis,…
03 Jul 23
The consideration includes $1.75bn in upfront cash and up to $750m in the form of potential milestone payments…
03 Jul 23
The approval in China was based on the results from the global Phase 3 ADAPT trial in which…
03 Jul 23
Both firms decided to voluntarily withdraw the US RET-mutant MTC indication following consultation with the FDA, as the…
03 Jul 23
The newly secured funding will be utilised to expand operations and further advance the development of its groundbreaking…
03 Jul 23
This project will also be supported by $15 million in state funding from the New Hampshire Department of…
03 Jul 23
Cyltezo is the only adalimumab biosimilar with Phase III comparative clinical studies in rheumatoid arthritis, plaque psoriasis and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Jun 23
Under the NEURii collaboration, partners will pool their expertise in therapeutics, technology development and commercialisation, health data management…